Rocket Lab Keeps Faltering So Why Does One Big Bank Currently Expect 100% Upside?

Rocket Lab shares trade at $63.92 vs a $112.94 consensus target (~77% upside), including KeyBanc’s $135 target (~111% upside), but the stock remains under pressure (-8.37% YTD; -57%+ from the $151 high). Q2 revenue rose 62% YoY to $234.07M (beat), yet GAAP EPS was -$0.08 vs -$0.0767 due to $8.576M acquisition costs; integration and timing risk (Neutron window narrowing) are key cautions. Backlog jumped 137% YoY to $2.36B with $1.0B+ of new Q3 contracts, while management frames meaningful cash-flow improvement as a 2027 story contingent on Neutron’s first test flight.

Analysis

RKLB is still trading like a pre-product company with a financing overhang, not like a scaled industrial: the market is discounting the probability-weighted path, not the sell-side endpoint. The biggest second-order issue is dilution elasticity — every delay in Neutron raises the odds that growth is funded through equity rather than operating cash, which caps upside even if backlog keeps compounding. That makes the stock sensitive to execution misses much more than to headline contract wins.

The more interesting winner/loser dynamic is within the space complex. If RKLB proves Neutron on time, it expands the credible non-SpaceX launch market and should tighten valuation for launch-adjacent names, but until then it mainly creates a read-through discount for higher-risk peers like ASTS and LUNR that also need continuous capital access and perfect milestone delivery. Conversely, defense-linked demand supports the thesis that the category has real end-market tailwinds, but those tailwinds do not protect margins if program integration costs or launch slips keep cash burn elevated.

The contrarian view is that the Street may be underpricing the optionality of a successful first flight, but overpricing how quickly that success translates into cash flow. The key window is 1-3 months for milestone risk and 6-18 months for operating leverage; if pad delivery slips or the company leans again on capital raises, the multiple can compress further despite a strong backlog. What would falsify the bullish case is a cleanly communicated Neutron schedule, no incremental dilution, and evidence that acquisition integration is not dragging gross margin lower on a run-rate basis.

Key Decisions for Investors

• Do not chase the consensus target outright; wait for a confirmed Neutron milestone or a post-rally pullback before initiating any long RKLB exposure.
• For tactical upside, use a 6-12 month RKLB call spread only after the first credible launch-date confirmation; the trade is a low-premium way to express rerating optionality while capping dilution risk.
• If you want relative-value exposure, consider a short RKLB / long cash-flow-proven aerospace-defense basket (e.g., XAR or ITA) into the next 1-3 month catalyst window; the risk is a sharp squeeze if launch timing is reaffirmed.
• Watch for any additional ATM usage or integration charges larger than expected; that is the cleanest signal to de-risk, because it would convert a growth story into a capital-structure story.